Cancer markers and methods of use thereof
A cancer, cancer cell technology, applied in vaccines, carbohydrase inhibitor compounds and compositions thereof, treatment or detection of hyperproliferative diseases and/or conditions, selection of markers for cancer stem cells, antibody and/or immunogenic binding It can solve the problem of insufficient concentration of CSC, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0514] Preparation of antibody-drug conjugates
[0515] In the antibody-drug conjugate (ADC) of the present invention, the antibody (Ab) is bound to one or more drug moieties (D) via a linker (L), eg, about 1 to about 20 drug moieties per antibody. ADCs of formula I can be prepared by several routes using organic chemistry reactions, conditions and reagents known to those skilled in the art, including: (1) reaction of the nucleophilic group of the antibody with a divalent linker reagent, via co- A valent bond forms Ab-L, which subsequently reacts with the drug moiety D; and (2) the nucleophilic group of the drug moiety reacts with a divalent linker reagent to form D-L via a covalent bond, which subsequently reacts with the nucleophilic group of the antibody reaction. Additional methods of making ADCs are described herein.
[0516] Ab-(L-D)pI
[0517]A connector can consist of one or more connector components. Exemplary linker components include 6-maleimidocaproyl ("MC"), m...
example
[0583] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of ordinary skill in the art should, in light of the present invention, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or a similar result without departing from the spirit and scope of the invention.
example 1
[0584] Example 1: Exemplary Synthesis of SSEA3 Analogs
[0585] Process 1.
[0586] Compound Gb4 analogs, ATP, UTP, galactose analogs, phosphoenolpyruvate, magnesium chloride and enzymes galactokinase (GalK), UDP sugar pyrophosphorylase (AtUSP), β-1,3-galactosyl Transferase (LgtD), pyruvate kinase (PK) and inorganic pyrophosphatase (PPA) were combined in solution, the reaction was initiated at room temperature with pH controlled at 7.0, and the reaction was monitored by TLC until no more product was observed. After the reaction was complete, the protein in the reaction mixture was removed by heating for 30 minutes, followed by centrifugation and filtration with a 0.22 μΜ filter. The filtrate was then purified by C-18 gel chromatography. Fractions were collected and monitored by TLC.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More